Figure 4: Percentage of Patients With 35% and 50% Reduction in FIAS and TCS, Patients With Coexisting ASD

Figure 4 % patients with 35% or 50% reductions ASD

Percentage of Patients With 35% and 50% Reduction in FIAS and TCS by Time Point, Patients With Coexisting ASD at Baseline

Format

PNG

Source

Zynerba Pharmaceuticals, Inc.

Downloads